Erasca (ERAS) Share-based Compensation (2020 - 2026)
Erasca posted quarterly Share-based Compensation of $8.5 million for Q1 2026, up 26.02% year-on-year from $6.7 million in Q1 2025, and up 45.29% on a QoQ basis from $5.8 million in Q4 2025.
Erasca (ERAS) has 7 years of Share-based Compensation data on file, last reported at $8.5 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 26.02% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $26.6 million (down 0.72% YoY), and the FY2025 full-year result was $24.9 million, down 7.69% from the prior year.
- Share-based Compensation for Q1 2026 stood at $8.5 million, up from $5.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.5 million in Q1 2026 and bottomed at $4.4 million in Q1 2022.
- The 5-year median for Share-based Compensation is $6.3 million (2024), against an average of $6.3 million.
- The widest annual swing landed in 2022, when Share-based Compensation surged 458.74%; it then slipped 10.89% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $5.4 million in 2022, then rose by 14.05% to $6.1 million in 2023, then rose by 2.8% to $6.3 million in 2024, then fell by 7.69% to $5.8 million in 2025, then soared by 45.29% to $8.5 million in 2026.
- The last three Share-based Compensation figures came in at $8.5 million (Q1 2026), $5.8 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 8.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.46 Mn |
| Mar 31, 2026 | 8.46 Mn |
| Dec 31, 2025 | 5.82 Mn |
| Dec 31, 2025 | 5.82 Mn |
| Sep 30, 2025 | 5.97 Mn |
| Sep 30, 2025 | 5.97 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Mar 31, 2025 | 6.71 Mn |
| Mar 31, 2025 | 6.71 Mn |
| Dec 31, 2024 | 6.31 Mn |
| Dec 31, 2024 | 6.31 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Dec 31, 2023 | 6.14 Mn |
| Dec 31, 2023 | 6.14 Mn |
| Sep 30, 2023 | 6.24 Mn |
| Sep 30, 2023 | 6.24 Mn |
| Jun 30, 2023 | 7.01 Mn |
| Jun 30, 2023 | 7.01 Mn |
| Mar 31, 2023 | 6.85 Mn |
| Mar 31, 2023 | 6.85 Mn |
| Dec 31, 2022 | 5.38 Mn |
| Dec 31, 2022 | 5.38 Mn |
| Sep 30, 2022 | 5.23 Mn |
| Sep 30, 2022 | 5.23 Mn |
| Jun 30, 2022 | 5.06 Mn |
| Jun 30, 2022 | 5.06 Mn |
| Mar 31, 2022 | 4.44 Mn |
| Mar 31, 2022 | 4.44 Mn |
| Dec 31, 2021 | 2.88 Mn |
| Dec 31, 2021 | 2.88 Mn |
| Sep 30, 2021 | 3.02 Mn |
| Sep 30, 2021 | 3.02 Mn |
| Jun 30, 2021 | 1.64 Mn |
| Jun 30, 2021 | 1.64 Mn |
| Mar 31, 2021 | 795,000.00 |
| Mar 31, 2021 | 795,000.00 |
| Dec 31, 2020 | 407,000.00 |
| Dec 31, 2020 | 407,000.00 |
| Sep 30, 2020 | 176,000.00 |
| Sep 30, 2020 | 176,000.00 |
| Jun 30, 2020 | 109,000.00 |
| Jun 30, 2020 | 109,000.00 |